Pfizer COVID-19 Vaccine - BMJ Whistleblower | FULL INTERVIEW

BRITISH MEDICAL JOURNAL (BMJ), 2021
Covid-19: Researcher Blows the Whistle on Data Integrity Issues in
Pfizer’s Vaccine Trial https://www.bmj.com/content/bmj/375/bmj.n2635.full.pdfShow more

Brook Jackson, a now-fired regional director at Ventavia Research Group, revealed to The BMJ that vaccine trials at several sites in Texas last year had major problems – including:
- Falsifying data
- Unblinding trial subjects
- Failing to report adverse events in subjects
- Failing to follow up with subjects with adverse events
- Failing to test subjects suspected of being infected

"A regional director who was employed at the research organization Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson, emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day. Jackson has provided The BMJ with dozens of internal company documents, photos, audio recordings, and emails."